Antifungals for systemic use;Antifúngicos para uso sistémico

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 27, Issue 6, 2009, Pages 353-362

  Ruiz Camps, Isabel ^a   Cuenca Estrella, Manuel ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Amphotericin B; Azole; Echinocandins

Indexed keywords

ALFENTANIL; AMITRIPTYLINE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTACID AGENT; ANTIFUNGAL AGENT; CARBAMAZEPINE; CASPOFUNGIN; CYCLOSPORIN A; DIDANOSINE; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; FLUINDOSTATIN; IMIDAZOLE DERIVATIVE; ISAVUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; MICONAZOLE; MIDAZOLAM; MYCOGRAB; NYSTATIN; PHENYTOIN; POSACONAZOLE; SORDARIN; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ASPERGILLUS TERREUS; CANDIDIASIS; COLITIS; CRYPTOCOCCOSIS; DIARRHEA; DRUG CROSS REACTIVITY; DRUG MECHANISM; DRUG SAFETY; FUSARIUM; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HISTOPLASMA CAPSULATUM; HUMAN; HYPOCALCEMIA; LIVER DYSFUNCTION; MYCOSIS; NAUSEA AND VOMITING; NEPHROTOXICITY; PAECILOMYCES LILACINUS; PARACOCCIDIOIDES BRASILIENSIS; RECOMMENDED DRUG DOSE; REVIEW; SCEDOSPORIUM; SKIN MANIFESTATION; STREPTOMYCES; VOMITING;

EID: 67849094110     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2009.04.001     Document Type: Article

References (41)

1. J. Gavalda, and I. Ruiz [Guidelines for the treatment of infection due to Aspergillus spp] Enferm Infecc Microbiol Clin 21 2003 571 578
2. J. Gavalda, and I. Ruiz [Guidelines for the treatment of invasive fungal infection. Invasive fungal infection by Candida spp. Invasive Fungal Infection Study Group (MICOMED) and Infection in Transplantation Study Group (GESITRA) of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC)] Enferm Infecc Microbiol Clin 21 2003 498 508
3. J. Pachon, J.M. Cisneros, A.R. Collado-Romacho, J.M. Lomas-Cabezas, L.-N. Lozano, and J. Parra-Ruiz [Treatment of invasive fungal infections. 2005. Andalusian Infectious Disease Society.] Enferm Infecc Microbiol Clin 24 2006 254 263
4. M.J. Ruping, J.J. Vehreschild, and O.A. Cornely Patients at high risk of invasive fungal infections: when and how to treat Drugs 68 2008 1941 1962
5. T.J. Walsh, J.L. Goodman, P. Pappas, I. Bekersky, D.N. Buell, and M. Roden Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study Antimicrob Agents Chemother 45 2001 3487 3496
6. M. Cuenca-Estrella, A. Gomez-Lopez, E. Mellado, M.J. Buitrago, A. Monzon, and J.L. Rodriguez-Tudela Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi Antimicrob Agents Chemother 50 2006 917 921
7. J.W. Baddley, D.K. Benjamin Jr, M. Patel, J. Miro, E. Athan, and B. Barsic Candida infective endocarditis Eur J Clin Microbiol Infect Dis 27 2008 519 529
8. J.R. Wingard, M.H. White, E. Anaissie, J. Raffalli, J. Goodman, A. Arrieta L Amph/ABLC Collaborative Study Group A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia Clin Infect Dis 31 2000 1155 1163
9. A. Gomez-Lopez, O. Zaragoza, J.L. Rodriguez-Tudela, and M. Cuenca-Estrella Pharmacotherapy of yeast infections Expert Opin Pharmacother 9 2008 2801 2816
10. P.G. Pappas, C.A. Kauffman, D. Andes, D.K. Benjamin Jr, T.F. Calandra, and J.E. Edwards Jr Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America Clin Infect Dis 48 2009 503 535
11. T.J. Walsh, E.J. Anaissie, D.W. Denning, R. Herbrecht, D.P. Kontoyiannis, and K.A. Marr Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America Clin Infect Dis 46 2008 327 360
12. O.A. Cornely, J. Maertens, M. Bresnik, R. Ebrahimi, A.J. Ullmann, and E. Bouza Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) Clin Infect Dis 44 2007 1289 1297
13. V. Monforte, P. Ussetti, R. Lopez, J. Gavalda, C. Bravo, and A. De Pablo Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety J Heart Lung Transplant 28 2009 170 175
14. B.J. Rijnders, J.J. Cornelissen, L. Slobbe, M.J. Becker, J.K. Doorduijn, and W.C. Hop Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial Clin Infect Dis 46 2008 1401 1408
15. M. Cuenca-Estrella, T.M. Diaz-Guerra, E. Mellado, and J.L. Rodriguez-Tudela Flucytosine primary resistance in Candida species and Cryptococcus neoformans Eur J Clin Microbiol Infect Dis 20 2001 276 279
16. R.J. Bruggemann, J.W. Alffenaar, N.M. Blijlevens, E.M. Billaud, J.G. Kosterink, and P.E. Verweij Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents Clin Infect Dis 48 2009 1441 1458
17. A. Bohme, M. Ruhnke, D. Buchheidt, O.A. Cornely, H. Einsele, and R. Enzensberger Treatment of invasive fungal infections in cancer patients - recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) Ann Hematol 88 2009 97 110
18. B.J. Kullberg, J.D. Sobel, M. Ruhnke, P.G. Pappas, C. Viscoli, and J.H. Rex Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial Lancet 366 2005 1435 1442
19. R. Herbrecht, D.W. Denning, T.F. Patterson, J.E. Bennett, R.E. Greene, and J.W. Oestmann Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 2002 408 415 (Pubitemid 34851833)
20. T.J. Walsh, P. Pappas, D.J. Winston, H.M. Lazarus, F. Petersen, and J. Raffalli Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever N Engl J Med 346 2002 225 234 (Pubitemid 34438861)
21. M.M. Roden, T.E. Zaoutis, W.L. Buchanan, T.A. Knudsen, T.A. Sarkisova, and R.L. Schaufele Epidemiology and outcome of zygomycosis: a review of 929 reported cases Clin Infect Dis 41 2005 634 653
22. D. Andes, A. Pascual, and O. Marchetti Antifungal therapeutic drug monitoring: established and emerging indications Antimicrob Agents Chemother 53 2009 24 34
23. A. Pascual, T. Calandra, S. Bolay, T. Buclin, J. Bille, and O. Marchetti Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes Clin Infect Dis 46 2008 201 211
24. O.A. Cornely, J. Maertens, D.J. Winston, J. Perfect, A.J. Ullmann, and T.J. Walsh Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia N Engl J Med 356 2007 348 359
25. A.J. Ullmann, J.H. Lipton, D.H. Vesole, P. Chandrasekar, A. Langston, and S.R. Tarantolo Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease N Engl J Med 356 2007 335 347
26. D.W. Denning Echinocandins: a new class of antifungal J Antimicrob Chemother 49 2002 889 891
27. M. Cuenca-Estrella, A. Gomez-Lopez, E. Mellado, A. Monzon, M.J. Buitrago, and J.L. Rodriguez-Tudela Analysis of the activity profile in vitro of micafungin against spanish clinical isolates of common and emerging species of yeasts and moulds Antimicrob Agents Chemother 53 2009 2192 2195
28. T.R. Rogers, and S. Frost Newer antifungal agents for invasive fungal infections in patients with haematological malignancy Br J Haematol 144 2009 629 641
29. J. Mora-Duarte, R. Betts, C. Rotstein, A.L. Colombo, L. Thompson-Moya, and J. Smietana Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2002 2020 2029
30. T.J. Walsh, H. Teppler, G.R. Donowitz, J.A. Maertens, L.R. Baden, and A. Dmoszynska Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N Engl J Med 351 2004 1391 1402
31. T.E. Zaoutis, H.S. Jafri, L.M. Huang, F. Locatelli, A. Barzilai, and W. Ebell A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients Pediatrics 123 2009 877 884
32. A.C. Reboli, C. Rotstein, P.G. Pappas, S.W. Chapman, D.H. Kett, and D. Kumar Anidulafungin versus fluconazole for invasive candidiasis N Engl J Med 356 2007 2472 2482
33. D.K. Benjamin Jr, T. Driscoll, N.L. Seibel, C.E. Gonzalez, M.M. Roden, and R. Kilaru Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections Antimicrob Agents Chemother 50 2006 632 638
34. E.R. Kuse, P. Chetchotisakd, C.A. Da Cunha, M. Ruhnke, C. Barrios, and D. Raghunadharao Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial Lancet 369 2007 1519 1527
35. F. Queiroz-Telles, E. Berezin, G. Leverger, A. Freire, Van der Vyver, and T. Chotpitayasunondh Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial Pediatr Infect Dis J 27 2008 820 826
36. M. Cuenca-Estrella Combinations of antifungal agents in therapy -what value are they? J Antimicrob Chemother 54 2004 854 869
37. J.H. Rex, P.G. Pappas, A.W. Karchmer, J. Sobel, J.E. Edwards, and S. Hadley A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects Clin Infect Dis 36 2003 1221 1228
38. S. Perkhofer, V. Lechner, and C. Lass-Florl In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing Antimicrob Agents Chemother 53 2009 1645 1647
39. A.C. Pasqualotto, and D.W. Denning New and emerging treatments for fungal infections J Antimicrob Chemother 61 2008 i19 i30
40. M.A. Ghannoum, H.G. Kim, and L. Long Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis J Antimicrob Chemother 59 2007 556 559
41. J. Pachl, P. Svoboda, F. Jacobs, K. Vandewoude, H.B. Van Der, and P. Spronk A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis Clin Infect Dis 42 2006 1404 1413